Product Description
Mechanisms of Action: PG Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Colombia | Dominican Republic | Jordan | Korea | Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Guowei Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Gastritis
Phase 1: Edema|Flushing
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20222548 | P1 |
Completed |
Flushing|Edema|Gastritis |
2022-11-10 |
|
| CTR20130427 | P2 |
Active, not recruiting |
Gastritis |
None |